Introduction: A Significant Trademark Ruling

The Bombay High Court recently delivered an important ruling in favour of Sun Pharmaceutical Industries Ltd., granting interim relief in a trademark dispute concerning the use of the mark “Pantozed.” The Court restrained another party, Zawadi Healthcare Limited, and its Indian manufacturer from using “PANTOZED-40” for an anti-acidity drug on the ground that it bears a deceptive similarity to Sun Pharma’s well-established medicine “Pantocid.” This decision highlights the judiciary’s strict approach toward trademark protection in the pharmaceutical sector, where even minor confusion can have serious implications for public health.

Court’s Observation on Deceptive Similarity

Justice Sharmila Deshmukh noted that the suffixes “ZED” and “CID” create confusion among consumers, as they are phonetically similar. The Court emphasized that such resemblance amounts to deceptive similarity, particularly in the context of medicinal products.

Background of the Dispute

The dispute arose when Sun Pharma filed a suit alleging infringement of its registered trademark “Pantocid,” a widely used medication for treating acidity. The company asserted that it has been using the mark since 1998 and has built substantial goodwill and reputation over the years. The defendant, a foreign healthcare company along with its Indian manufacturer, was using the mark “Pantozed-40” for a drug containing the same active ingredient, pantoprazole. Sun Pharma argued that the similarity between the two marks was likely to mislead consumers, pharmacists, and medical practitioners, thereby creating a risk of confusion in the market.

To know more about this, click the link below 

Reliance on Supreme Court Precedent

While examining the case, the Bombay High Court focused on the phonetic and structural resemblance between the two marks. It observed that “Pantocid” and “Pantozed” share a similar prefix and that their suffixes, when pronounced, sound alike. The Court relied on the principles laid down in Cadila Healthcare Ltd. v. Cadila Pharmaceuticals Ltd., which established strict standards for trademark similarity in the pharmaceutical sector. The judgment emphasized that the test for similarity must be applied more strictly in this field because confusion between drug names can directly affect patient safety.

Prima Facie Case and Grant of Injunction

The Court found that Sun Pharma had established a strong prima facie case for trademark infringement. It noted that the plaintiff’s mark had been in continuous and extensive use for over two decades, whereas the defendant’s mark was relatively recent. Additionally, the defendant did not hold a valid trademark registration in India, which weakened its position. Considering these factors, the Court granted an interim injunction restraining the use of “Pantozed” or any similar mark until further proceedings.

Export as Trademark Use under Indian Law

An important aspect of this case was the defendant’s argument that the goods were manufactured in India solely for export and not sold domestically. On this basis, the defendant claimed there was no infringement within India. However, the Court rejected this contention and clarified that manufacturing goods in India for export still constitutes “use” of a trademark under the Trade Marks Act, 1999. This interpretation significantly broadens the scope of trademark protection.

Rejection of Passing Off Claim

Despite granting relief on the ground of trademark infringement, the Court did not accept Sun Pharma’s claim of passing off. Passing off requires proof of misrepresentation and damage to goodwill. Since the products were not sold in the Indian market, the Court found no evidence of actual confusion or harm within the country. Therefore, the passing off claim was not sustained.

Implications for the Pharmaceutical Industry

This ruling has far-reaching implications for the pharmaceutical industry. It reinforces the need for companies to exercise caution while choosing brand names, especially for medicinal products. The judgment underscores that courts will adopt a stricter standard when assessing similarity between drug names due to potential risks to human health.

Conclusion: Strengthening Trademark Protection

Overall, the decision of the Bombay High Court strengthens the framework of trademark protection in India and sends a clear message about the importance of distinct and non-deceptive branding. It reflects a balanced approach by protecting established trademarks while distinguishing between infringement and passing off. As the pharmaceutical industry expands globally, this judgment is likely to serve as an important precedent in future trademark disputes.